Phase 3 TRIUMPH-4 demonstrated 28.7% mean weight loss at 68 weeks with the 12 mg dose, confirming the exceptional Phase 2 results (24.2% at 48 weeks
This discrepancy likely underlies the repeated failure of copper-targeted interventions in clinical translation [254]
10.1016/J.NEUROSCIENCE.2014.11.047 88 JohnsonD
Common indications include: Pernicious anaemia an autoimmune condition where the stomach cannot produce intrinsic factor, a protein necessary for B12 absorption [8] [9] Malabsorption disorders including Crohn's disease, coeliac disease, or following gastric surgery Strict vegan or vegetarian diets with confirmed deficiency though high-dose oral B12 may be sufficient if no malabsorption exists Certain medications such as metformin or proton pump inhibitors that may interfere with B12 absorption [9] [10] Neurological symptoms including peripheral neuropathy, memory problems, or balance difficulties related to deficiency Diagnosis should be confirmed through blood tests measuring serum B12 levels, full blood count, folate, and often anti-intrinsic factor antibodies
However, judges are not supposed to decide which side has the better scientific interpretation when both sides are using reliable scientific methods
